Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 3rd Preview)
-
Novartis expands China-origin mRNA T-cell engager deal
Novartis has agreed to pay Abogen Biosciences $575 million upfront for exclusive worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager designed to reset B cells by in vivo production of the engager. The agreement, reported via deal coverage, values the partnership at up to ~$7.8 billion in potential development, regulatory, and commercial milestones depending on options exercised. The transaction follows a pattern of large pharma using China-based platforms to replenish early pipeline assets. Abogen retains non-exclusive rights to its broader RNA platform development outside the licensed programs, with the company expected to advance ABO2203 toward later-stage trials under Novartis oversight. For investors and developers, the structure underscores how mRNA-encoded “engager” programs are shifting from concept to scaled partnering, with attention on the ability to manage target engagement kinetics while maintaining safety in autoimmune indications.
-
Phase 3 evERA confirms oral giredestrant plus everolimus survival gain in metastatic breast cancer
Results from the phase 3 evERA Breast Cancer study in the New England Journal of Medicine show that adding giredestrant to the mTOR inhibitor everolimus nearly doubles survival without progression in metastatic breast cancer. The all-oral combination delivered a clinically meaningful extension of time on therapy endpoints versus control. The data place an endocrine pathway degrader strategy alongside established mTOR combinations, targeting a population where resistance to standard therapies remains a persistent challenge. Clinicians will now weigh efficacy signals against tolerability and patient selection considerations for real-world use. The trial’s publication in a leading journal is likely to accelerate downstream discussions around sequencing with CDK4/6 inhibitors and fulvestrant-class options, particularly for hormone receptor–positive, HER2-negative disease.
-
Biotech financing: Immix CAR-T offering follows interim NEXICART-2 amyloidosis response
Immix Biopharma moved quickly after an interim readout from its Phase II NEXICART-2 trial for BCMA-targeted CAR-T NXC-201 in light-chain (AL) amyloidosis. Days of investor attention intensified when the company announced a $125 million offering shortly after reporting an 89% complete response rate among 45 patients with interim data. The follow-on financing—underwritten by J.P. Morgan—signals that Immix intends to sustain operations and prepare regulatory activities, with management indicating a planned BLA submission next year and final study data expected to close out NEXICART-2. For the sector, the pairing of strong interim efficacy with rapid capital raises highlights demand for new CAR-T constructs in amyloidosis as developers try to secure timelines toward approval.
-
Clinical development funding: AnaCardio raises €62.5M for oral AC01 in advanced HFrEF
AnaCardio raised €62.5 million (about $70.5 million) in a Series B to advance AC01, an oral calcium-sensitizing contractile agent targeting chronic advanced heart failure with reduced ejection fraction (HFrEF). The company said the financing fully funds AC01’s Phase IIb push, aiming for Phase III readiness by 2028. AC01 is a ghrelin-mimetic small molecule originally in-licensed from Helsinn in 2022, with Phase Ib/IIa results published in The Lancet. AnaCardio also reported positive scientific advice from both the FDA and EMA on development direction. The round—co-led by Novo Holdings and the Ljungström family office—adds to the growing set of heart failure efforts testing differentiated mechanisms beyond standard neurohormonal blockade.
-
Regulatory science: FDA to highlight aging and longevity in next FARS update
The FDA plans to add aging and longevity to topics highlighted in its updated Focus Areas of Regulatory Science (FARS) report, according to remarks by FDA Chief Scientist Steven Kozlowski at the Aging Research & Drug Discovery Meeting. The updated FARS is expected early in fiscal 2027, with no specific publication date provided. Kozlowski emphasized the need for regulatory-accepted, pre-competitive endpoints that could support feasible clinical trial designs across aging-related conditions. Acting Chief of Staff Lowell M. Zeta framed the move as an inflection point for how FDA adapts to evolving science. In parallel, the FDA indicated it is working to establish shared endpoints that can serve as a bridge between biological and clinical measurement approaches, potentially shaping how developers design and justify trials in longevity and healthspan programs.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.